For growing-phase melanoma cases, medicinal treatments have been remarkably developed with the incorporation of immune inhibitor types and selective therapy such as BRAF and mitogen-activated protein kinase (MEK) inhibitors and programmed cell death ligand-1 (PDL-1) blockage (Ribas et al., 2020). This evidence concerns the gene CD274 and melanoma.